Glucocorticoids promote Von Hippel Lindau degradation and Hif-1α stabilization by Vettori, A et al.
Glucocorticoids promote Von Hippel Lindau
degradation and Hif-1α stabilization
Andrea Vettoria,1, David Greenaldb,c,d,1, Garrick K. Wilsone,1, Margherita Perona, Nicola Facchinelloa,
Eleanor Markhamb, Mathavan Sinnakaruppanc,d, Laura C. Matthewsf, Jane A. McKeatingg,2,3, Francesco Argentona,2,3,
and Fredericus J. M. van Eedenb,2,3
aDepartment of Biology, University of Padova, I-35121 Padova, Italy; bBateson Centre, Department of Biomedical Science, University of Sheffield, Sheffield
S10 2TN, United Kingdom; cLee Kong Chian School of Medicine, Nanyang Technological University, 639798, Singapore; dGenome Institute of Singapore,
138672, Singapore; eInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT,
United Kingdom; fLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James’s University Hospital, Leeds LS9
7TF, United Kingdom; and gNuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, United Kingdom
Edited by Gregg L. Semenza, Johns Hopkins University School of Medicine, Baltimore, MD, and approved July 25, 2017 (received for review April 3, 2017)
Glucocorticoid (GC) and hypoxic transcriptional responses play a central
role in tissue homeostasis and regulate the cellular response to stress
and inflammation, highlighting the potential for cross-talk between
these two signaling pathways. We present results from an unbiased
in vivo chemical screen in zebrafish that identifies GCs as activators of
hypoxia-inducible factors (HIFs) in the liver. GCs activated consensus
hypoxia response element (HRE) reporters in a glucocorticoid receptor
(GR)-dependent manner. Importantly, GCs activated HIF transcriptional
responses in a zebrafish mutant line harboring a point mutation in the
GR DNA-binding domain, suggesting a nontranscriptional route for GR
to activate HIF signaling. We noted that GCs increase the transcription
of several key regulators of glucose metabolism that contain HREs,
suggesting a role for GC/HIF cross-talk in regulating glucose homeo-
stasis. Importantly, we show that GCs stabilize HIF protein in intact
human liver tissue and isolated hepatocytes. We find that GCs limit
the expression of Von Hippel Lindau protein (pVHL), a negative reg-
ulator of HIF, and that treatment with the c-src inhibitor PP2 rescued
this effect, suggesting a role for GCs in promoting c-src–mediated
proteosomal degradation of pVHL. Our data support a model for
GCs to stabilize HIF through activation of c-src and subsequent
destabilization of pVHL.
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Glucocorticoids (GCs) are steroid hormones secreted from theadrenal glands that regulate carbohydrate, lipid, and protein
metabolism. GCs are widely used as anti-inflammatory agents for
treating pathological conditions where hypoxia plays a role in disease
progression such as rheumatoid arthritis and chronic obstructive
pulmonary disease. GCs and hypoxia pathways have a close interplay
in physiology and disease (1–3); however, recent studies report
conflicting results on the cross-talk between GC action and hypoxia
(4, 5). Hypoxia-inducible factors (HIFs) are oxygen-sensitive tran-
scriptional complexes constituted by α- and β-subunits that activate
diverse pathways regulating cellular glucose and lipid metabolism
and proliferation (6, 7). Under normoxic conditions, the HIF-1α
transcriptional subunit is recognized by prolyl hydroxylases and tar-
geted for degradation via the Von Hippel Lindau (VHL)-mediated
ubiquitin proteasome pathway; however, under hypoxic conditions
HIF-1α is stabilized and translocates to the nucleus to exert its
transcriptional activity. HIFs play a central role in many disease
processes and provide a therapeutic target for treating pathological
conditions including cancer, ischemia, stroke, inflammation, and
chronic anemia (8–11). Screens to identify agents that stabilize HIFs
have identified numerous agents, with the majority acting either via
iron chelation or as 2-oxyglutarate analogs (12). In vitro HIF-
reporter screening methods, although extremely valuable, do not
provide physiological information and may overlook tissue-specific
activators that require a physiological context.
To identify regulators of the HIF pathway, we developed sev-
eral HIF-reporter zebrafish lines (13) and completed an unbiased
chemical screen. GCs activated HIF-associated transcriptional
responses most prominently in the liver. Importantly, we translate
these observations to human tissue and show that GCs stabilize
HIF in primary human hepatocytes and intact liver slices. Our
data support a model where GCs act via a transcriptional in-
dependent mechanism by activating c-src to repress Von Hippel
Lindau (pVHL) expression and stabilize HIF protein under nor-
moxic conditions. Our study identifies a role for GCs to stabilize
HIF and to regulate liver glucose metabolism.
Results
GCs Activate Hypoxic Signaling. Prolyl hydroxylase 3 (PHD3) tran-
scription is regulated by HIFs, and we used our zebrafish phd3:eGFP
HIF-reporter line to screen a chemical library (Dataset S1) for HIF
activators. Dimethyloxaloylglycine (DMOG), a well-established ac-
tivator of HIF signaling, was used as a positive control (14). Of the
41 initial hits, several GCs activated the reporter to comparable
levels as DMOG (60 μM) (Fig. 1A). We confirmed that two GR
agonists, betamethasone 17,21-dipropanoate (BME) and dexa-
methasone (DEX), activated the reporter (Fig. 1 B and C). We
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noted increased phd3-GFP expression mainly in the liver (Fig.
1B), suggesting that activation may be due to nonspecific stress
as result of drug metabolism. To address this potential issue,
reporter embryos were treated with GCs in the presence or ab-
sence of the GR antagonist RU-486 that reduced GFP intensity
of BME-treated embryos (Fig. 1 B and C), while having minimal
effect on DMOG-dependent activation (Fig. 1C), demonstrating
that GC-augmented phd3:eGFP activity is GR-dependent.
To characterize the effects of BME on endogenous hypoxia-
associated transcriptional responses, we quantified selected HIF-
responsive genes (pfkfb3, p4ha1b, and hpx) and GR-responsive genes
(tsc22d3, scarb1, fkbp5, and pepck1) (15–17) by qPCR. phd3:eGFP
embryos [5 days postfertilization (dpf)] were treated with BME
(10 μM) for 8 h before isolating RNA, the optimal time for phd3
induction. (Fig. S1). BME induced the transcription of HIF-target
genes to variable extents, albeit less than in a vhl mutant back-
ground, with hpx being the most responsive gene (Fig. 1D). To
determine whether BME activation of phd3:eGFP reporter is HIF
dependent, we silenced Hif-1β expression, an essential binding
partner of both HIF-1α and HIF-2α (18). Hif-1β morphants were
incubated with BME from 56 h postfertilization (hpf) until 72 hpf,
and HIF-1β knockdown significantly reduced GFP intensity in the
treated embryos compared with control morpholino (MO)-injected
embryos (Fig. 1E), demonstrating that GC activation of phd3:eGFP
is HIF-dependent.
To confirm that GCs directly activate HIF-transcriptional activ-
ity, we created a HIF reporter zebrafish expressing tandem copies
of a hypoxia response element (HRE) driving eGFP expression,
named Tg(4xhre-tata:eGFP)ia21. Reporter activity is decreased in
Hif-1β morphants and increased by expression of a dominant active
form of HIF-1α mRNA or DMOG treatment, confirming that the
transgene responds to modulators of the HIF-1–signaling pathway
(Fig. 2 and Fig. S2). To examine the influence of GCs, the offspring
obtained from a Tg(4xhre-tata:eGFP)ia21 carrier were exposed to
increasing concentrations of DEX for 24 h. Treated embryos
showed a dose-dependent activation of the 4xhre-tata transgene,
confirming that GCs activate HIF transcriptional responses under
normoxic conditions (Fig. 3A and Fig. S3A). To independently as-
sess whether GCs affect HIF-1 signaling and the glycolytic pathway,
we analyzed the expression of three known hypoxia-dependent
regulators of glucose metabolism in zebrafish (19) using whole-
mount in situ hybridization (WISH); as expected, pfkfb3, ldha, and
glut1 were up-regulated after DEX treatment as a consequence of
HIF-1 activation (Fig. S3B).
GC Activation of HIF Is Independent of GR DNA Binding. GCs regulate
gene transcription through binding and activating cytoplasmic
GR, through nuclear translocation, and through direct binding to
GC response elements (GRE) (20). To analyze the mechanism
Fig. 1. Identification of glucocorticoids as HIF activators. (A) Retest of hits from
the Spectrum screen for activators of the HIF response in phd3:eGFP zebrafish,
where compounds showing an average GFP level of >44 are shown. Averaged
maximum pixel intensity and SEM are shown for between five and nine em-
bryos. Dark gray: controls; black: GC-like compounds; light gray: non-GC hits.
AMC, amcinonide; BME, betamethasone; CBP, clobetasol propionate; CPO,
ciclopirox olamine; DEX, dexamethasone; DFL, 8,2-dimethoxyflavone; FLC,
fluocinonide; HAL, halcinonide; HCB, hydrocortisone butyrate; ICA, icariin;
NIN, 7-nitroindazole; PTE, ptaeroxylin; TAA, triamcinolone acetonide; TAD,
triamcinolone diacetate. (B) BME activates phd3:eGFP in an RU-486–dependent
manner; representative images show the activation specific to the liver in BME-
treated embryos and reduced GFP expression following BME+RU-486 cotreat-
ment. (Magnification: 16×.) (C) Quantitation of phd3:eGFP response. DMSOwas
added to 1% vol/vol in all experiments except Control (C), DMOG to 60 μM, and
RU-486 to 5 μM as indicated (n ≥ 9). (D) BME induction of hypoxia-regulated
genes and GC target genes, where values above bars indicate average fold
change (FC) and triplicate samples of 20 embryos were used. For the
hypoxia-induced genes, FC induction in vhlmutants vs. wild type is given as a
comparison, where FC is calculated using ΔΔCT ± SEM. (E) HIF1β-MO abro-
gates BME activation of phd3:eGFP. Maximum pixel intensity in embryos as
grouped by injection showing mean ± SEM (n = 14). Significance was cal-
culated using Kruskal–Wallis one-way ANOVA followed by Dunn’s multiple
comparison test for treatments against DMSO (*P < 0.05; **P < 0.01; ***P <
0.001; ****P < 0.0001).
Fig. 2. Generation of 4xhre-tata Hif-reporter lines. (A) Schematic representa-
tion of the Tol-2 vector used to generate the Tg(4xhre-tata:eGFP)ia21 line. The
construct consists of a 98-bp fragment encoding four HREs (in red) from the
murine lactate dehydrogenase followed by a TATA minimal promoter (in
boldface), EGFP (in green), and the poly(A) signal. (B–D) Representative image of
Tg(4xhre-tata:eGFP)ia21 embryos at 48 hpf injected with a control MO (B) or the
HIFβ-MO MO (C). (Magnification: 5×.) Down-regulation of Hifβ significantly
decreases transgene activity as reported by the integrated density analysis of
fluorescence (D). (E–G) HIf-1α dominant active (DA) mRNAs injected in Tg(4xhre-
tata:eGFP)ia21 embryos increase transgene expression (F) compared with control
embryos (E). (Magnification: 5×.) (H–J) Treatment from 72 hpf to 96 hpf with
100 μM DMOG significantly increases 4xhre-tata transgene activity (I) with re-
spect to the control embryos (H). (Magnification: 4×.) (D, G, and J) Average
values of fluorescence integrated density calculated for treated embryos and
controls. Values represent the mean ± SEM (***P < 0.001; **P < 0.01; *P < 0.05).
A.U., arbitrary units.











underlying GC/HIF cross-talk, we assessed whether DEX-induced
effects on HIF-reporter activity were dependent on GR and its
DNA binding activity. Single-cell stage Tg(4xhre-tata:eGFP)ia21
embryos were microinjected with a splice-blocking MO against
full-length GR (gr-MO) (21). Real-time PCR analysis of fkbp5
showed significantly reduced expression to confirm gr-MO activity
(Fig. S3C). Morphants and control Tg(4xhre-tata:eGFP)ia21 em-
bryos (48 hpf) were incubated with or without DEX (10 μM) for
24 h, and reporter activity was measured. DEX increased 4xhre-
tata activity in controls but had minimal effect on the grmorphants
(Fig. 3 B and C). Moreover, HIF activation was independently
confirmed by measuring endogenous phd3 mRNA expression in
72-hpf gr morphants and control embryos (Fig. 3D). Finally, GR
dependency of HIF transcriptional activation was observed in a
CRISPR-induced null mutant of the GR gene (Fig. S3D).
We also studied the zebrafish grs357mutant (22) that lacks DNA-
binding function and abrogates GR transcriptional activity (Fig. 4A).
Interestingly, DEX activated the Tg(4xhre-tata:eGFP)ia21 reporter
in a grs357 mutant background (Fig. 4B), suggesting that a non-
transcriptional mechanism underlies GC activation of HIF sig-
naling. To independently assess the role of the GR DNA-binding
domain in GC/HIF cross-talk, offspring from two grs357 homo-
zygous carriers (72 hpf) were incubated with DEX or BME, and
phd3 mRNA levels were analyzed by WISH (Fig. 4 C–E). DEX
and BME activated phd3 transcription in both wild-type and grs357
mutant embryos, confirming that HIF transcriptional activity was
preserved.
GCs Activate HIF Signaling in Human Hepatocytes. To verify whether
the GC/HIF cross-talk observed in zebrafish is relevant to humans,
we focused our efforts on human liver-derived cells. Culturing
hepatocyte-derived Huh-7 cells under low oxygen stabilized HIF-
1α at comparable levels to prednisolone treatment (Fig. 5 A and
B). To assess transcriptional responses, Huh-7 cells were trans-
fected with a hre-luciferase (hre-luc) reporter and treated with
prednisolone and dexamethasone that activated the reporter (Fig.
5C). Furthermore, prednisolone induced mRNA levels of three
endogenous HIF target genes (VEGF, PDK, and GLUT1) to a
similar degree as low-oxygen treatment, thus paralleling the in vivo
results observed in zebrafish embryos (Fig. 5D). Furthermore, GC
activation of HRE activity was sensitive to the GR antagonist RU-
486 (Fig. 5D), demonstrating GR dependency. Next we screened a
panel of hypoxia-regulated target genes in Huh-7 cells and found
that 29/38 HIF target genes were induced by prednisolone, whereas
only 3 of 38 were induced by cortisone (Dataset S2).
To confirm that the response is not simply a result of using
immortalized Huh-7 cells, we showed that prednisolone activated
the HRE reporter in primary human hepatocytes (Fig. 5E). To
ascertain whether GCs increase HIF expression and associated
transcriptional activity in an authentic liver microenvironment, we
treated human liver slices with prednisolone or culture under low
oxygen (3%) for 16 h and imaged nuclear HIF-1α (Fig. 6A) and
quantified HIF target gene mRNA levels (Fig. 6 B and C). Both
prednisolone and low-oxygen treatments stabilized HIF-1α (Fig.
6A) and increased HIF target gene expression (Fig. 6 B and C).
Together, these data demonstrate that, as in the zebrafish, GCs
can activate HIF signaling in the human liver.
To determine how GCs activate HIF signaling, we investigated
the effect of GCs on pVHL expression, a crucial negative regulator
of HIFα protein. We showed that GCs reduce pVHL expression in
Huh-7 cells (Fig. 6D). This is unlikely to be mediated by a tran-
scriptional mechanism since VHL mRNA levels were not affected
(Fig. S4A). pVHL is degraded by the proteasome (Fig. 6D) fol-
lowing posttranslational modification by kinases such as c-src and
CKII (24). Indeed, we found that inhibiting c-src activity with PP2
(25) rescued the inhibitory effects of GC on VHL expression (Fig.
6E), blocked HIF-1α induction (Fig. 6F), and normalized HIF
Fig. 3. Cross-talk between the HIF-1 and glucocorticoid-signaling pathways is
mediated by the glucocorticoid receptor and HREs. (A) The 72-hpf Tg(4xhre-tata:
eGFP)ia21 embryos were incubated with different concentrations of DEX. DEX
activates the 4xhre-tata transgene. (Magnification: 8×.) (B) Images of 72-hpf
Tg(4xhre-tata:eGFP)ia21 larvae injected with a gr-MO and a CTRL-MO alone or
combined with DEX (Bottom). DEX activation of 4xhre-tata transgene expression
is maintained in CTRL-MO–injected larvae and ablated in GR morphants.
(Magnification: 8×.) (C) Histograms showing the average values (±SEM) of the
fluorescence-integrated density in 72-hpf Tg(4xhre-tata:eGFP)ia21 embryos in-
jected with gr-MO and CTRL-MO with or without DEX. A.U., Arbitrary units.
(D) Fold changes (±SEM) in phd3 gene expression in 72-hpf embryos injected
with gr-MO and CTRL-MO with or without DEX (24 h) compared with non-
treated/noninjected controls (set at 1). Target gene mRNA levels were normal-
ized to β-actin. *P < 0.05; ***P < 0.001.
Fig. 4. Glucocorticoid induction of HIF-1 activity is independent of glucocorticoid
receptor DNA binding. (A) Treatment with 10 μMDEX for 24 h activates the wild-
type Tg(9xGCRE-HSV.Ul23:eGFP)ia20 (23) glucocorticoid reporter (GRE-reporter)
line, while in grs357 mutant background (Right) DEX is unable to activate GRE
reporter. (Magnification: 14.5×.) (B) Images of wild-type and grs357 embryos in the
Tg(4xhre-tata:eGFP)ia21 background (HRE-reporter), treated for 24 h with DEX
10 μM. DEX activates the 4xhre-tata transgene in both wild-type and grs357 mu-
tant larvae and induces a significant and generalized increase of fluorescence that
is particularly evident in the liver (L in Insets). (Magnification: 14.5×; Insets, 72.5×.)
(C–E) In situ hybridization of phd3mRNA antisense probe in wild-type and grs357
mutants at 80 hpf. (Magnification: 17.5×.) DEX (D) or BME (E) activated
phd3 gene expression in the liver (arrowheads).
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target gene expression (Fig. S4B), suggesting a mechanism for GCs
to stabilize HIFs via degrading VHL.
Discussion
The Spectrum Collection (Microsource Discovery Systems) in-
cludes compounds that modulate a wide variety of pathways;
however, only GCs showed a consistent and robust HIF activation.
It is surprising that GCs were not previously identified as HIF
modifiers in cell-based chemical screens. We can only speculate
what the apparent liver specificity of the GC effect may have con-
tributed. Thus, in vivo chemical screens, providing a variety of cell
types in a physiological context, are a useful expansion compared
with more classical screening approaches, even with “well-trodden”
pathways like HIF.
We confirmed that GCs promote HRE-dependent HIF tran-
scriptional activity in fish and human liver cells. Surprisingly, fish
expressing a GRmutant lacking a functional DNA-binding domain
(DBD) still activated the phd3 promoter and 4xhre reporter
models after treatment with DEX. However, complete knockdown
of GR and a newly generated truncated GR mutant abrogated the
ability of DEX to stabilize HIF. The GR is essential for survival as
demonstrated by the report that 90% of GR KO mice die soon
after birth (26) and only 10% of GR KO zebrafish survive, with a
reduced fitness. Of note, both mouse and zebrafish homozygous
mutants of the GR-DBD survive with minor defects (22, 27),
suggesting essential roles for GRE-independent GR activities, as
exemplified by our study.
Since GCs are reported to activate c-src kinase (28, 29), which is
known to phosphorylate and target pVHL for proteosomal deg-
radation (24), we hypothesized a role for GCs in stabilizing HIF
via c-src degradation of VHL. Consistent with our results, RU-
486 inhibited such nongenomic effects of GR (30). Our in vitro
studies confirm that GCs destabilize VHL protein expression, and
this was rescued by cotreating cells with the c-src inhibitor PP2
(Fig. 6E). As VHL is a negative regulator of HIF, this results in
HIF expression under normoxic conditions.
Although we see activation of phd3 and 4xhre promoters and
other hypoxia response genes by GCs, GCs do not fully replicate
a hypoxic response. We find increased expression of many HIF
target genes (Dataset S2), but some exceptions were noted such
as Enolase1 and Carbonic anhydrase 9, which were down-
regulated by prednisolone. A direct interaction between ligand-
activated GR and HIF proteins cannot be excluded, as Kodama
et al. (5) have suggested that GR binds the HIF dimer. However,
a simpler explanation is that, in addition to stabilizing HIF
protein, GR binds a subset of promoters to regulate transcrip-
tion. A complex interplay is suggested by other reports: for ex-
ample, while HIF up-regulates VEGF expression and promotes
angiogenesis, GCs are generally angiostatic (31) and negatively
regulate VEGF expression (32–34). Similarly, during high alti-
tude sickness, GC and HIF may have apparently opposing effects
(35, 36). Therefore, we propose that the interplay that we have
identified is likely to be tissue- and possibly context-specific.
We found that GC agonists increased mRNA levels of the
classical HIF target erythropoietin both in cell culture (Dataset S2)
and in zebrafish embryos and adult zebrafish livers (Fig. S5). Our
data are consistent with reports showing a synergistic effect of GCs
and HIFs in hematopoiesis (37, 38), and it will be interesting
to investigate whether this cooperativity is GR-DBD–dependent.
GCs received their name because they promote blood glucose
levels as well as gluconeogenesis and glycogen storage in the liver
and provide an acute response to stress (39). HIF signaling has a
profound impact on cellular metabolism and induces gluconeo-
genesis and glycogen storage (40, 41). We suggest that GCs
modulation of VHL and HIF may contribute to their ability to
modulate blood glucose and glycogen storage. In addition, HIF has
been shown to impact lipid metabolism in the liver, where its
(in)appropriate activation reduces beta oxidation and increases
lipid storage capacity leading to steatosis (42, 43). It is worth noting
that long-term treatment with GCs was reported to increase
Fig. 5. Glucocorticoids stabilize HIF in human cell lines. (A) Mock or prednisolone-
treated (100 nM) Huh-7 cells were stained for HIF-1α expression (green) and
counterstained with DAPI (gray); images show nuclear localization of HIF-1α.
(Magnification: 260×.) (B) HIF-1α expression in hypoxic (3% O2) and predniso-
lone (Pred)-treated Huh-7 cells. (C) Huh-7 cells were transfected with a HRE
luciferase reporter and 24 h later treated with increasing doses of various ste-
roids (100 nM) for16 h. GC agonists activated the HRE reporter while 17OH did
not. (D) Huh-7 cells treated with Pred/RU-486 (100 nM) for 24 h, lysed, and
RNA-purified to quantify HIF transcriptional targets. Data represents fold
change over control sample (Dataset S2). (E) Huh-7 cells and primary human
hepatocytes (PHH) were transfected with a HRE luciferase reporter and 24 h
later treated with Pred (100 nM) and/or RU-486 (100 nM) for 16 h, and HRE
luciferase activity was measured. ***P < 0.001; ns, not significant (ANOVA).
Data are represented as mean ± SD.
Fig. 6. Glucocorticoids stabilize HIF in human liver slices. (A) HIF-1α expression
in human liver slices treated with prednisolone or cultured under low oxygen
(3%) for 24 h and counterstained with DAPI. Both prednisolone and hypoxic
treatments induce nuclear HIF-1α expression. Images are representative of five
donor livers. (Magnification: 55×.) (B and C) HIF target gene PDK1 and VEGF
mRNA levels in human liver slices from three donors treated with Pred/RU-
486 for 24 h. (D) VHL expression in Huh-7 cells treated with prednisolone (Pred)
or dexamethasone (Dex) in presence or absence of proteasome inhibitor MG-
132 at 10 μM. (E and F) Huh-7 cells treated with prednisolone (Pred) or dexa-
methasone (Dex) in presence or absence of Src inhibitor PP2 at 5 μM and
probed for VHL (E) or HIF-1α (F). All samples were stained for actin as a loading
control. ***P < 0.001; ns, not significant (ANOVA). Data are represented as
mean ± SD.











steatosis (44). Activation of the HIF pathway via cross-talk with the
GR may explain how GC excess regulates hepatic fat metabolism
and the steatotic phenotype. Our experiments show that GCs
predominantly stabilize HIF in the liver and may activate only a
subset of HIF targets, which could be addressed by studying tissue-
specific knockout models. Based on the elegant experiments of
Rankin et al. (43), we would predict that liver-specific deletion of
HIF-2a should protect mice from GC-induced steatosis and may
reduce the effect of GCs on blood glucose levels.
It is becoming clear that HIF signaling is regulated not only by
low oxygen, but also by several other inflammatory mediators (45–
47). Our data support GC as a further key modulator of HIF
signaling to add to this growing list. It is interesting to note that
many common GC and HIF gene targets are implicated in regu-
lating hepatic metabolism. This is potentially important, as GCs are
secreted in a rhythmic circadian fashion, where circulating GC
levels reach a maximum to coincide with the onset of the active
phase—morning in humans, evening in mice. Since metabolic
processes in the liver are coupled to the circadian clock, our data
provide an additional level of control, where GC activation of the
HIF pathway helps to ensure that the changing metabolic demands
throughout the day are met. Our data suggest a role for GC-driven
circadian components in other aspects of HIF signaling.
Material and Methods
Zebrafish Strains. vhl mutant and Tg(phd3:eGFP)i144/i144 (13) fish were main-
tained in a mixed Tupfel long fin/London wild-type (TL/LWT) background. The Tg
(9xGCRE-HSV.Ul23:eGFP)ia20 line is a GC pathway reporter (23). The zebrafish GR
mutant line grs357 was incrossed to create homozygotes (22). To obtain wild-type
embryos, LWTs were incrossed. To obtain homozygous vhl mutants, vhlhu2117/+;
phd3:eGFPi144/i144 fish were incrossed. Embryos were incubated at 28 °C in E3
(5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mMMgCl2, pH 7.2) containing
methylene blue (Sigma-Aldrich) at 0.0001%. The generation of Tg(4xhre-tata:
eGFP)ia21 and Tg(4xhre-tata:mCherry, cmlc2:eGFP)ia22 reporters and GR CRISPR
mutation is described in SI Text.
Drug Treatment of Embryos. The Spectrum Collection (Microsource Discovery
Systems) of 2,000 compounds was used; tested compounds and detailed
methods can be found in SI Text and Dataset S1.
Hypoxic Target Gene Activation in Zebrafish. Three biological replicates of 10
phd3:EGFPi144/i144 embryos were treated for 8, 12, 24, 36, and 48 h starting
from 72 hpf. Embryos were treated with 10 μM betamethasone 17,21 dipro-
panoate and 60 μM DMOG in 1% DMSO, with untreated and 1% DMSO
controls. The vhlhu2117/hu2117; phd3:EGFPi144/i144mutants were used as positive
controls. Biological replicates of 48-hpf Tg(4xhre-tata:eGFP)ia21 embryos were
incubated with or without 10 μM DEX and/or 3.8 μM 17-AAG (Sigma) for 24 h.
RNA was isolated using TRIzol and quantified using the Nanodrop ND-
1000 spectrophotometer. cDNA was reverse-transcribed from 0.5 μg RNA using
the SuperScript III First-Strand Synthesis System (Invitrogen). For the temporal
phd3 expression profile, qPCR was performed with optimized primers, using
the iCycler iQ system (Bio-Rad). Cycling conditions were the following: 95 °C −
3 min, [95 °C − 15 s, 60 °C − 30 s] × 40 cycles, 55–95 °C in 0.5-°C increments 30 s,
with β-actin2 as internal control. Primers: see Dataset S3. For hypoxia/gluco-
corticoid target gene detection, qPCR was carried out using the Applied Bio-
systems SDS Software v2.4.1 in conjunction with the 7900HT Fast Real-Time
qPCR System. The cycling conditions were the following: 50 °C − 2 min,
95 °C − 10 min, [95 °C − 15 s, 60 °C − 1 min] × 40 cycles. Primers: see Dataset S3.
Cycle threshold (Ct) values were calculated automatically using the software,
with ROX reference dye as the passive reference. Fold change was calculated
using the ΔΔCT method.
MO and mRNA Injections. The translation-blocking MO HIFβ-MO (GGATTAG-
CTGATGTCATGTCCGACA) was used as reported (18) while a splice-site targeting
MO (gr-MO) was used to silence GR (21). A standard control MO (CTRL-MO;
Genetools) was used as a negative control. The MO stock solution (8 mg/mL)
was diluted in Danieau’s solution, and ∼2 nL was injected per embryo as pre-
viously described (48). Dominant-active hif-1αa and hif-1αb (kindly provided by
P. Elks, University of Sheffield, Sheffield, UK) were synthesized (mMessage-
Machine; Ambion, Invitrogen) and injected as described in ref. 49.
Image Analysis in Tg(4xhre-tata:eGFP)ia21 Embryos. For analysis of Tg(4xhre-tata:
eGFP)ia21 embryos, fluorescence was collected using a Leica M165FC dissecting
microscope and a Nikon C2 H600L confocal microscope. N-phenylthiourea–
treated larvae were anesthetized with tricaine and embedded in 1% low-
melting agarose on a glass slide. Images were analyzed with Nikon software.
For fluorescence quantification of transgenic embryos, a Leica M165FC micro-
scope and DC500 digital camera were used. All images were acquired using
identical parameters, and fluorescence-integrated density was calculated
using ImageJ.
Cell Culture, Antibodies, and Treatments. Huh-7 and HEK293 cells were main-
tained in Dulbecco’s modified Eagle’s medium supplemented with 10% FBS,
1% L-glutamine, and 50 units/mL penicillin/streptomycin (Life Technologies).
Primary human hepatocytes were isolated as described (50) and maintained in
Williams E Medium (Sigma) supplemented with 10% FBS, 5 mM Hepes/insulin/
L-glutamine (Life Technologies). Cells were grown in a humidified incubator at
37 °C, 5% CO2, and 20% O2 (normoxia). For hypoxic conditions, cells were
grown at 37 °C in a humidified sealed Galaxy 48R incubator (New Brunswick)
at 37 °C, 5% CO2, 92% N2, and 3% O2 (hypoxia). The following antibodies
used: anti-mouse HIF-1α (Novus Biologicals), anti-VHL (Cell Signaling #2738),
Alexa Fluor goat anti-mouse 488 (Molecular Probes), anti–β-actin antibody
(Sigma Aldrich), anti-mouse and anti-rabbit HRP-conjugated secondary anti-
body (GE Healthcare). Prednisolone, dexamethasone, cortisone, RU-486 17OH
progesterone, and MG-132 are from Sigma Aldrich. Src inhibitor PP2 was
purchased from Merk Millipore.
Ex Vivo Liver Slices. Liver tissue samples were collected with local National
Health Service research ethics committee approval (Walsall LREC 04/Q2708/
40) and with written informed consent. Donor liver tissue surplus to trans-
plantation requirements were collected from the Queen Elizabeth Hospital.
Cores were cut from the tissue immediately upon receipt using a Krumdieck
Tissue Slicer (Alabama R&D) (51). Briefly, the core was placed into the slicer
assembly under aseptic conditions, and 240-μm sections were collected and
immediately transferred into Williams E media/1% L-glutamine/0.5 μM in-
sulin. An albumin ELISA (Bethyl Laboratories) was used to monitor the via-
bility of the slices. Samples from five donors were serum-starved followed by
incubation under hypoxia (3% O2) or normoxia (20% O2) for 24 h. Liver slices
were treated with prednisolone (100 nM) for 24 h before fixing for detection
of HIF-1α by confocal microscopy.
Confocal Microscopy on Cells. Cells were grown on 13-mm borosilicate glass
coverslips at a density of 4 × 104/well for 24 h and serum-starved for 5 h
before treating with prednisolone (100 nM). Cells or liver slices were fixed in
3% paraformaldehyde for 25 min at room temperature (RT) and per-
meabilized with 0.01% TX-100/PBS for 10 min. Cells were incubated with
anti–HIF-1α for 1 h at RT, unbound antibody was removed by washing, and
bound antibody was detected with Alexa-488 secondary antibody. Nuclei
were counterstained with 4′,6-diamidino-2-phenylindole, dihydrochlorine
(DAPI; Life Technologies). Cells were imaged using a Zeiss Meta Head con-
focal microscope with a 63× water immersion objective.
HRE Reporter Assay. Cells were transfected with the HRE reporter (a plasmid
containing four tandemHRE copies kindly provided byM. Ashcroft, Cambridge
University, Cambridge, UK) using Fugene 6 transfection reagent (Promega) per
the manufacturer’s guidelines. After 24 h, cells were serum-starved for 5 h
before treating with GC or RU-486, (100 nM) for a further 24 h. Cells were
lysed, and reporter activity was quantified using a firefly luciferase assay sys-
tem (Promega) in a luminometer (Berthold Lumat LB 9507).
Western Blotting. Cells were harvested in lysis buffer (PBS/1% Triton-X100/
0.1% Na deoxycholate/0.1% SDS) containing protease and phosphatase in-
hibitors (Roche). Lysates were clarified by centrifugation, and protein con-
centration was determined using a Bradford Protein Assay Reagent (Pierce).
Protein lysates (20 μg) were added to sample running buffer (30% glycerol/
6% SDS/0.02% bromophenol blue/10% 2-β-mercaptoethanol/0.2 M Tris·HCl;
pH 6.8) and separated by SDS/PAGE. Separated proteins were transferred to
PVDF membranes and incubated with primary antibodies before detection
with HRP-conjugated secondary antibody and enhanced chemiluminescence
(Geneflow) using a PXi imaging system (Syngene).
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